Venture Capitalists News Hubb
Advertisement Banner
  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact
No Result
View All Result
  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact
No Result
View All Result
Venture Capitalists News Hubb
No Result
View All Result
Home Venture Capital Market

The Capital Quest | Temasek bets on Motilal Oswal PE-backed diagnostics company

admin by admin
September 26, 2022
in Venture Capital Market


Goa-based Molbio Diagnostics, known for its ‘Truenat’ technology for real-time testing for diseases such as Covid-19 and dengue, said Monday that Singapore state investment firm Temasek has decided to invest $85 million (Rs 693 crore) in the company.

The fresh funds from Temasek, along with those from existing investors such as Motilal Oswal Alternates, will help the company accelerate development and commercialisation of new technologies based on clinical need gaps, Molbio said in a statement.

Molbio says its technology brings together a portable, battery-operated real-time polymerase chain reaction (PCR) platform that can be used for testing infectious diseases such as tuberculosis, Covid-19, Hepatitis-C, human papillomavirus, influenza as well as vector-borne diseases like dengue, chikungunya and malaria.

“The demand for high-quality, point-of-care molecular diagnostic systems is higher than ever today. The strategic partnership with Temasek will strengthen our ability to provide sustainable choices to address global healthcare challenges,” said Sriram Natarajan, Director and CEO, Molbio Diagnostics.

Molbio says its Truenat real-time PCR has been deployed in over 5,000 testing centres across over 40 countries.

In India, the government has deployed its devices at primary and community health centres across all states and Union Territories under the National Tuberculosis Elimination Program, it added.

Temasek joins the cap table two and a half years after Motilal Oswal Private Equity (MOPE), a subsidiary of financial services group Motilal Oswal Financial Services, inked a deal to invest up to Rs 240 crore ($32.75 million then) in Molbio. This was struck just before the Covid-19 pandemic hit the globe and pushed up demand for PCR testing.

Temasek has been on an investment spree in India, having clocked over a dozen transactions over the last 15 months. The Molbio deal adds to its recent bets in the healthcare sector in companies like regional hospital chain Medica Synergie and eyecare chain Dr Agarwal’s.

Related



Source link

Previous Post

Congress Presses State Department for Info on Costs, Benefits of Crypto

Next Post

GST authorities issue Rs 21,000Cr show-cause notice to Gameskraft Technology

Next Post

GST authorities issue Rs 21,000Cr show-cause notice to Gameskraft Technology

Recommended

Sam Bankman-Fried Issues Not-Guilty Plea in FTX Case

4 weeks ago

6 Projects Using NFTs for Social Good

1 month ago

The Capital Quest | SBICAP’s catalytic fund for stressed realty projects hits final close at $1.9 bn

2 months ago

Prosus values 9.7% stake in BYJU’s at $578M, cautions on macro-economic challenges

2 months ago

SushiSwap Head Chef Hit by Controversy in First Week

4 months ago

Edtech unicorn Unacademy lays off 10pc of workforce: report

3 months ago

© 2022 Venture CapitaLists News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Venture Capital Market
  • Venture Capital Funding
  • Contact

© 2022 Venture Capitalists News Hubb All rights reserved.